HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.

ABSTRACT:

Background

Chemoradiotherapy (CRT) is the standard of care for patients diagnosed with locally advanced cervical cancer (LACC), a human papillomavirus (HPV)-related cancer that relapses in 30%-60% of patients. This study aimed to (i) design HPV droplet digital PCR (ddPCR) assays for blood detection (including rare genotypes) and (ii) monitor blood HPV circulating tumor DNA (HPV ctDNA) levels during CRT in patients with LACC.

Methods

We analyzed blood and tumor samples from 55 patients with HPV-positive LACC treated by CRT in a retrospective cohort (n = 41) and a prospective cohort (n = 14). HPV-ctDNA detection was carried out by genotype-specific ddPCR.

Results

HPV ctDNA was successfully detected in 69% of patients (n = 38/55) before CRT for LACC, including nine patie

SUBMITTER: Cabel L 

PROVIDER: S-EPMC8164037 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature